Emergent Biosolutions Stock News

Vaughan Nelson Investment Management L.P. cut its stake in shares of Emergent BioSolutions Inc. (NYSE:EBS) by 1.9% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 336,680 shares of the biopharmaceutical company’s stock after selling 6,375 shares during the quarter. Vaughan Nelson […]

Emergent BioSolutions Inc. (NYSE:EBS) price on Friday, December 10, rose 0.15% above its previous days close as an upside momentum from buyers pushed the stocks value to $40.05. A look at the stocks price movement, the close in the last trading session was $39.99, moving within a range at $39.35 and $40.635. The beta value Thinking Of Buying Emergent BioSolutions Inc. (NYSE: EBS) Stock? Heres What You Need To Know Read More »

Vaccines Market Key Players Studied in this Report Are GlaxoSmithKline plc. (Brentford, United Kingdom), Sanofi (Paris, France), Pfizer Inc. (New York, United States), Merck & Co., Inc. (New Jersey, United States), Novartis AG (Basel, Switzerland), Emergent BioSolutions, Inc. (Maryland, United States), CSL Limited (Melbourne, Australia), Inovio Pharmaceuticals, Inc. (Pennsylvania, United States), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Osaka, Japan), Other Prominent Players. Vaccines Market Key Players Studied in this Report Are GlaxoSmithKline plc. (Brentford, United Kingdom), Sanofi (Paris, France), Pfizer Inc. (New York, United States), Merck & Co., Inc. (New Jersey, United States), Novartis AG (Basel, Switzerland), Emergent BioSolutions, Inc. (Maryland, United States), CSL Limited (Melbourne, Australia), Inovio Pharmaceuticals, Inc. (Pennsylvania, United States), Bavarian Nordic (Denmark), Mitsubishi Tanabe Pharma Corporation (Osaka, Japan), Other Prominent Players.

Emergent BioSolutions Inc. (NYSE:EBS) was the target of a large decrease in short interest in November. As of November 15th, there was short interest totalling 1,620,000 shares, a decrease of 47.1% from the October 31st total of 3,060,000 shares. Based on an average daily volume of 630,700 shares, the short-interest ratio is presently 2.6 days. []

Emergent Biosolutions with ticker code (EBS) have now 7 analysts in total covering the stock. The consensus rating is ''Buy''. The range between the high target price and low target price is between 120 and 63 with the average target price sitting at 85.71. Given that the stocks previous close was at 44.21 this indicates there is a potential upside of 93.9%. The 50 day MA is 47.9 and the 200 moving average now moves to 64.9. The company has a market capitalisation of $2,112m. Company Website: /> [stock_market_widget type="chart" symbol="EBS" chart="bar" range="6mo" interval="1d" line-color="rgb(49, 125, 189)"] Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response products and solutions for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company''s products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care.

Wells Fargo & Company MN lowered its position in Emergent BioSolutions Inc. (NYSE:EBS) by 36.9% in the 2nd quarter, Holdings Channel reports. The fund owned 291,058 shares of the biopharmaceutical companys stock after selling 170,494 shares during the quarter. Wells Fargo & Company MNs holdings in Emergent BioSolutions were worth $18,334,000 as of its most []

The Canadian health regulator said on Wednesday it would allow Johnson & Johnson to import its COVID-19 vaccine made at contract manufacturer Emergent BioSolutions Inc's plant in Baltimore, Maryland.

In today’s recent session, 0.69 million shares of the Emergent BioSolutions Inc. (NYSE:EBS) have been traded, and its beta is 0.92. Most recently the company’s share price was $42.30, and it changed around $2.43 or 6.09% from the last close, which brings the market valuation of the company to $2.11B. EBS at last check was … Emergent BioSolutions Inc. (NYSE: EBS) In 2021: Will It Be Worth Investing In? Read More »

Marshall Wace LLP acquired a new stake in Emergent BioSolutions Inc. (NYSE:EBS) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 111,423 shares of the biopharmaceutical companys stock, valued at approximately $7,019,000. Marshall Wace LLP owned 0.21% of Emergent BioSolutions at the end of the most []

Emergent BioSolutions Inc. (NYSE:EBS)s stock price shot up 4.7% during trading on Tuesday after an insider bought additional shares in the company. The stock traded as high as $40.47 and last traded at $39.71. 3,699 shares changed hands during trading, a decline of 99% from the average session volume of 651,249 shares. The stock had []

Credit Suisse AG lowered its position in shares of Emergent BioSolutions Inc. (NYSE:EBS) by 5.1% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 43,503 shares of the biopharmaceutical companys stock after selling 2,360 shares during the quarter. Credit Suisse AGs holdings in []

The modification/loss of a contract coupled with a weak earnings report sent the stock tumbling 40%.

Related Stocks: EBS ,

Emergent BioSolutions (NYSE:EBS) had its price objective trimmed by Chardan Capital from $92.00 to $75.00 in a research report report published on Wednesday morning, The Fly reports. The firm currently has a buy rating on the biopharmaceutical companys stock. A number of other research analysts have also commented on EBS. TheStreet lowered shares of Emergent []